Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18389
Title: A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort.
Authors: Pedrini, Steve;Gupta, Veer B;Hone, Eugene;Doecke, James;O'Bryant, Sid;James, Ian;Bush, Ashley I;Rowe, Christopher C;Villemagne, Victor L;Ames, David;Masters, Colin L;Martins, Ralph N
Affiliation: Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia
School of Medical Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
National Ageing Research Institute, Parkville, VIC 3052, Australia
Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Parkville, VIC 3052, Australia..
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia
Co-operative Research Centre for Mental Health, Carlton, VIC 3053, Australia
CSIRO Digital Productivity Flagship, Brisbane, QLD 4029, Australia
University of North Texas Health Science Center, Fort Worth, 76107, Texas, USA
Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA 6150, Australia
The Florey Institute, The University of Melbourne, Parkville, VIC 3052, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 25-Oct-2017
EDate: 2017-10-25
Citation: Scientific reports 2017; 7(1): 14057
Abstract: Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ε4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ε4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18389
DOI: 10.1038/s41598-017-14020-9
ORCID: 0000-0003-2863-0293
0000-0001-8259-9069
0000-0003-3910-2453
PubMed URL: 29070909
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.